share_log

Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.25

Benzinga ·  Jun 7 01:07

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $6 to $6.25.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment